Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
| Line 17: | Line 17: | ||
====A forumla for PSAD==== | ====A forumla for PSAD==== | ||
Benson ''et al.'':<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref> | |||
:<math>PASD = \frac{serum PSA}{volume}</math> | :<math>PASD = \frac{serum PSA}{volume}</math> | ||
:<math>volume = \frac{1}{2} D1 | Where: | ||
:<math>volume = \frac{1}{2} D1 \times D2 \times D3</math>. | |||
:D1, D2, D3 are the major axes. | :D1, D2, D3 are the major axes. | ||
Note: | Note: | ||
*The volume of an ellipsoid is: | *The volume of an ellipsoid is: | ||
::<math>\frac{4}{3}\pi D1 | ::<math>\frac{4}{3}\pi D1 \times D1 \times D3</math>. | ||
==See also== | ==See also== | ||
Revision as of 04:26, 30 July 2014
Prostate specific antigen, abbreviated PSA, is marker that is quite specific for the prostate.
General
- Quantity in the serum used to screen for prostate cancer.
- PSA immunostain useful for classifying a carcinoma as prostate carcinoma.
Serum PSA
- Normal - typically < 4.0 ng/mL.
- Increases with age.[1]
Prostate specific antigen density
- Abbreviated PSAD.
Better predictor than (unadjusted) serum PSA for:
- Gleason score upgrading on prostatectomy.[2]
- BPH versus cancer.[3][4]
A forumla for PSAD
Benson et al.:[3]
Where:
- .
- D1, D2, D3 are the major axes.
Note:
- The volume of an ellipsoid is:
- .
See also
References
- ↑ Ku JH, Ahn JO, Lee CH, et al. (September 2002). "Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity". Urology 60 (3): 475–9. PMID 12350489.
- ↑ Sfoungaristos S, Katafigiotis I, Perimenis P (2013). "The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era". Can Urol Assoc J 7 (11-12): E722–7. doi:10.5489/cuaj.374. PMC 3840515. PMID 24282465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840515/.
- ↑ 3.0 3.1 Benson MC, Whang IS, Pantuck A, et al. (March 1992). "Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer". J. Urol. 147 (3 Pt 2): 815–6. PMID 1371554.
- ↑ Verma A, St Onge J, Dhillon K, Chorneyko A (June 2014). "PSA density improves prediction of prostate cancer". Can J Urol 21 (3): 7312–21. PMID 24978363.